Willow Biosciences Inc Share Price Canadian Securities Exchange
Equities
CA97111B1076
Pharmaceuticals
Sales 2022 | 821K 600K 50.07M | Sales 2023 | 1.17M 857K 71.47M | Capitalization | 12.42M 9.08M 758M |
---|---|---|---|---|---|
Net income 2022 | -14M -10.23M -854M | Net income 2023 | -13M -9.5M -793M | EV / Sales 2022 | -0.95 x |
Net cash position 2022 | 15.01M 10.97M 915M | Net cash position 2023 | 1.63M 1.19M 99.28M | EV / Sales 2023 | 9.21 x |
P/E ratio 2022 |
-0.96
x | P/E ratio 2023 |
-0.95
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 72.66% |
Managers | Title | Age | Since |
---|---|---|---|
Chris Savile
CEO | Chief Executive Officer | - | 12/19/12 |
Travis Doupe
DFI | Director of Finance/CFO | - | 12/19/12 |
Trish Choudhary
CTO | Chief Tech/Sci/R&D Officer | - | 01/19/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jim Lalonde
CHM | Chairman | 63 | 21/23/21 |
Donald Archibald
BRD | Director/Board Member | 63 | 12/19/12 |
Director/Board Member | 51 | 12/19/12 |
1st Jan change | Capi. | |
---|---|---|
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.35B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |